||Recombinant Human IGFBP6 was expressed in Insect cells.
||IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP6 is produced by bone cells and is the major IGF-BP present in cerebrospinal fluid, and specifically inhibits IGF-II actions. IGF-BP6 has been shown to inhibit IGF-II-dependent cancers such as neuroblastoma, colon cancer and rhabdomyosarcoma.
||Determined by its ability to inhibit IGF-II induced proliferation of human MCF-7 cells. The expected ED50 for this effect is 0.1 – 0.4 μg/ml.
||Recombinant human IGF-BP6 has a calculated mass of 22.6 kDa and consists of 213 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain. IGF-BP6 migrates at an apparent molecular weight of approximately 23.0-30.0 kDa by SDS-PAGE analysis under non-reducing conditions.
||RCPGCGQGV QAGCPGGCV EEEDGGSPA EGCAEAEGC LRREGQECG VYTPNCAPG LQCHPPKDD EAPLRALLL GRGRCLPAR APAVAEENP KESKPQAGT ARPQDVNRR DQQRNPGTS TTPSQPNSA GVQDTEMGP CRRHLDSVL QQLQTEVYR GAQTLYVPN CDHRGFYRK RQCRSSQGQ RRGPCWCVD RMGKSLPGS PDGNGSSSC PTGSSG
||Above 95% as determined by SDS-PAGE Analysis.